Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Sigilon

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Mar 25, 2021 10:06am

141 Views

Post# 32874571

RE:RE:RE:RE:RE:RE:RE:Sigilon

I didn't want examples, I wanted a specific reason why a reverse split would be bad for this company.. SVA. How would anyone here respond if management (instead of Me) did state they were going after an uplisting and consolidating? And I have to agree this discussion is going nowhere. &**&#^+** :)

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages